Pasithea Therapeutics Corp.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| By: | /s/ Dr. Tiago Reis Marques |
|---|---|
| Dr. Tiago Res Marques | |
| Chief Executive Officer and Director (Principal Executive Officer) | |
| Date: March 24, 2025 | |
| By: | /s/ Daniel Schneiderman |
|---|---|
| Daniel Schneiderman | |
| Chief Financial Officer (Principal Financial and Accounting Officer) | |
| Date: March 24, 2025 | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Tiago Reis Marques | Chief Executive Officer and Director | March 24, 2025 |
| Dr. Tiago Reis Marques | (Principal executive officer) | |
| /s/ Daniel Schneiderman | Chief Financial Officer | March 24, 2025 |
| Daniel Schneiderman | (Principal financial and accounting officer) | |
| /s/ Prof. Lawrence Steinman | Director | March 24, 2025 |
| Prof. Lawrence Steinman | ||
| /s/ Simon Dumesnil | Director | March 24, 2025 |
| Simon Dumesnil | ||
| /s/ Dr. Emer Leahy | Director | March 24, 2025 |
| Dr. Emer Leahy | ||
| /s/ Alfred Novak | Director | March 24, 2025 |
| Alfred Novak | ||
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
| Page | |
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PCAOB ID# 688 | F-2 |
|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS: | |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.